Emerging roles of CD133 in the treatment of gastric cancer, a novel stem cell biomarker and beyond

Gastric cancer (GC) is an aggressive disease with one of the highest mortality rates in the world. In the early stage, most patients are asymptomatic and early diagnosis is difficult. Recently, cancer stem cells (CSCs) have been highlighted as crucial emerging factors in the initiation or invasiveness of solid tumors. CD133, a CSC marker, is highly expressed in various tumors including gastric cancer. CD133-positive cells showed elevated malignant biological behaviors and CD133 upregulation is related to chemoresistance, cancer relapse, and poor prognosis. CD133 also plays an important role in the progression of tumors and metastasis. This review sum-marizes the current knowledge of the role of CD133 expression in GC and aims to contribute at identifying promising new strategies for treatment and management of gastric cancer.

Automated summary

CD133, a CSC marker, is highly expressed in gastric cancer and is associated with malignant behaviors, chemoresistance, and poor prognosis. It also plays an important role in tumor progression and metastasis.